
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
4503 | Tokyo | JPY | Delayed | |
ALPMY | OTC Markets | USD | Delayed | |
4503 | Frankfurt | EUR | Delayed |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kenji Yasukawa | 63 | 2017 | Chairman of the Board |
Naoki Okamura | 61 | 2016 | President, CEO & Director |
Takashi Tanaka | 67 | 2021 | Independent Outside Director |
Mika Nakayama | 63 | 2022 | Independent Outside Director |
Yoichi Ohno | 63 | 2023 | Outside Independent Director |
Masahiro Miyazaki | 70 | 2023 | Outside Independent Director |
Rika Hirota | - | - | Director |
Rie Akiyama | 54 | 2023 | Outside Independent Director |
Eriko Sakurai | 64 | 2022 | Independent Outside Director |
Tomoko Aramaki | 56 | 2024 | Outside Independent Director |
Katsuyoshi Sugita | 58 | 2021 | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director |
Mark Joseph Enyedy | 61 | - | Independent Outside Director |
Andreas Busch | 62 | 2025 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review